Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s

Data Presented at CNS Summit 2014 Supports Commencement of Phase 2 Clinical Trial in Alzheimer’s Patients NEW YORK, NY, November 17, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) announced full data results from the Phase 1 clinical trial of ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s, which…

Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference

NEW YORK, NY, November 10, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS), and various types of cancer, is pleased to announce the upcoming presentation of complete Phase 1 clinical trial…

Anavex to Present at SeeThruEquity Investor Conference in New York City

New York, NY – November 6, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, will be featured at the SeeThruEquity Fall Microcap Investor Conference in New…

Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease

New York, NY – November 3, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL) announced today that it has received regulatory approval from the Ethics Committee in Australia to initiate a Phase 2a clinical trial of its proprietary compound, ANAVEX 2-73, as well as ANAVEX PLUS, the combination of ANAVEX 2-73…